GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.
Shares of Nuvalent, Inc (NASDAQ:NUVL) rose sharply in pre-market trading after GSK agreed to acquire the company in a deal valued at $10.6 billion (7.9 billion pounds).
GSK will pay $124 per share in cash, a 40% premium over Nuvalent's closing share price on Monday.
Nuvalent shares jumped 38.2% to $122.56 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers CCSC Technology International Hldngs Ltd (NASDAQ:CCTG) gained 651.2% to $3.60 in pre-market trading.
Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK buys US biopharma company Nuvalent for $10.6B
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
Nuvalent vola a Wall Street: titolo in rialzo di quasi il 40% dopo l’annuncio dell’acquisizione da 10,6 miliardi di dollari da parte di Gsk | MilanoFinanza News
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. |…
Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40%…
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
